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Therapy of heart failure. The incidence and prevalence of heart one-year survival for advanced cardiac failure (NYHA
failure is on the rise. It has become the single most expensive class IV) [2, 3] and a 45 to 55% five-year survival in less
health care item in the United States and the number one severe cases (NYHA class II to III) [4].discharge diagnosis in the elderly. The goals of therapy include
In recent years, there have been several importantboth prevention and treatment of heart failure. In recent years
research studies and randomized clinical trials have revolution- breakthroughs in the therapy of heart failure. New ad-
ized the understanding of the pathophysiology and treatment vances in the treatment of cardiac failure include the
of this disease. This article focuses on the medical management development of successful transplantation programs andof chronic systolic heart failure based on the pathophysiology of
the development of drug therapy proven to improvethe disease. Systolic heart failure is characterized by a decrease
in left ventricular function and cardiac output, which results morbidity and mortality in heart failure patients, such
in activation of several neurohormonal compensatory systems. as angiotensin-converting enzyme (ACE) inhibitors and
The long term effects of this neurohormonal activation leads
b blockers.to further deterioration of cardiac function. The use of hydra-
Heart failure is a dynamic process starting with anlazine and nitrates to reduce the systemic vascular resistance
insult to the myocardium, which results in activation ofwas the first to show an improvement in mortality and morbid-
ity. Then angiotensin converting enzyme inhibitors, by inhib- the adrenergic, renin-angiotensin-aldosterone, and vaso-
iting the renin angiotensin system, demonstrated a greater im- pressin systems. This neurohormonal activation main-
provement in mortality and morbidity. More recently the
tains blood pressure and therefore is of benefit initially,inhibition of the sympathetic stimulation with beta-blockers
but may become deleterious over the long term. Thehas been shown to have an additive effect on morbidity and
mortality in combination with angiotensin-converting enzyme long-term goals for treating heart failure include treating
inhibitors. Digoxin and diuretics remain important for improv- any underlying or causative factors and attenuating the
ing symptoms and decreasing hospitalizations but have not
deleterious effects of neurohormonal activation.been shown to decrease mortality. The most recent advance
in the treatment of cardiac failure is the demonstration that
the aldosterone antagonists, spironolactone decreases morbid-
CAUSES OF HEART FAILUREity and mortality.
There are two major mechanisms by which cardiac
failure occurs normally: systolic dysfunction and diastolic
Heart failure is a pathologic state in which the heart dysfunction. The most common causes of systolic dysfunc-
is unable to maintain an adequate cardiac output to meet tion are coronary artery disease (ischemic cardiomyopa-
the metabolic requirements of peripheral tissues. Heart thy), hypertension, valvular heart disease, and idiopathic
failure is the single most expensive health care item in dilated cardiomyopathy. The classic causes of diastolic
the United States, causing an estimated $38 billion in dysfunction include chronic hypertension with left ven-
annual direct cost of care and accounting for approxi- tricular hypertrophy (LVH), diabetes mellitus, hypertro-
mately 1 million hospital admissions each year [1]. Mor- phic cardiomyopathy, aortic stenosis with normal LV func-
tality from heart failure remains high, with a 30 to 50% tion, and hypertensive hypertrophic cardiomyopathy of
the older population. The initial Framingham study pub-
lished in 1985 demonstrated that hypertension was theKey words: systolic dysfunction, diastolic dysfunction, coronary heart
disease, myocardial infarction, hypertension, vasoconstriction. most common cause of systolic heart failure [5]. How-
ever, more effective treatment of hypertension has re-
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NEUROHORMONAL CHANGES IN these two drugs in the Veterans Administration Cooper-
ative Study (V-HeFT-I) provided the first demonstrationHEART FAILURE
of improvement in survival and exercise tolerance inThe signs and symptoms of low-output cardiac failure
patients with congestive heart failure [11]. Isosobide dini-are in part due to the adaptive mechanisms that the
trate is usually given in doses of 20 to 60 mg three timesbody uses in an attempt to compensate for the primary
a day and hydralazine 50 to 75 mg every six hours.decrease in cardiac output. Neurohormonal adaptations,
such as activation of the renin-angiotensin-aldosterone,
sympathetic nervous and vasopressin systems, can con- ANGIOTENSIN-CONVERTING
tribute to the maintenance of the perfusion of vital or- ENZYME INHIBITORS
gans in low-output cardiac failure by two mechanisms.
The mechanisms by which ACE inhibitors exert their
First, these vasoconstrictor systems maintain the sys-
beneficial effects are not completely understood. After-
temic arterial pressure by increasing the systemic vascu-
load reduction does not seem to be the only mechanism,
lar resistance and next by an increase in cardiac output
since other agents that reduce afterload to the same
secondary to increasing myocardial contractility and en-
degree have not been shown to be of benefit. There are
hancing renal sodium and water retention, which results
other mechanisms in addition to blocking the effect of
in expansion of intravascular volume [7–9].
angiotensin on resistance vessels that may contribute to
There are, however, several maladaptive consequences
the beneficial effect of ACE inhibitors in cardiac failure.
of these neurohormonal changes: (1) Sodium and water
Angiotensin II mediates myocardial hypertrophy, in-
retention and venoconstriction can lead to pulmonary
creases fibrosis and collagen deposition, and causes acti-
and peripheral edema. (2) An increase in myocardial
vation of the sympathetic nervous system [9, 10]. There-
contractility and heart rate secondary to the activation of
fore, the administration of ACE inhibitors can decrease
the sympathetic nervous system may worsen myocardial
myocardial remodeling and hypertrophy, decrease the
ischemia and also cause life-threatening arrhythmias. (3)
activation of the sympathetic system, and reverse the
An increase in cardiac afterload caused by arterial vaso-
down-regulation of the angiotensin receptors. Finally,
constriction can worsen both systolic and diastolic ven-
ACE is a kininase, and its inhibition leads to a decrease
tricular function. (4) Finally, angiotensin II can increase
in the degradation of bradykinin, which is a well-knownmyocardial collagen deposition and fibrosis, which may
vasodilator that can reduce cardiac afterload. Moreover,impair both systolic and diastolic ventricular function [10].
bradykinin stimulates nitric oxide, which can suppressLong-term activation of these neurohormonal com-
cardiac myocyte proliferation.pensatory mechanisms may therefore have detrimental
In the V-HeFT-II trial, the use of the ACE inhibitoreffects. This has been the basis for the judicious interven-
enalapril in heart failure was shown to have greater im-tion with ACE inhibitors and b-adrenergic receptor
provement in survival than the combination of hydralaz-blockers in patients with cardiac failure. In prospective
ine and nitrates [12]. ACE inhibitors are now consideredrandomized studies, these classes of medication were
first-line treatment for patients with chronic heart failurefound to improve both symptoms and survival in heart
[13–15]. Several prospective randomized studies havefailure patients. Figure 1 represents the vicious cycle of
shown an improvement not only in symptoms and sur-systolic heart failure, with potential treatments for each
vival, but also a delay in the progression or worseningabnormality.
of heart failure with both enalapril and captopril. Initial
studies demonstrated the benefits of ACE inhibitors in
HYDRALAZINE AND NITRATES patients with severe congestive heart failure, and subse-
quently benefits were demonstrated in asymptomatic pa-As noted previously in this review, the activation of
tients with left ventricular dysfunction [16–21]. A recentthe renin-angiotensin-aldosterone, adrenergic, and vaso-
meta-analysis of 32 randomized placebo-controlled stud-pressin systems results in an increase in vascular tone
ies with ACE inhibitors in patients with different degreesand salt and water retention. These events result in an
of heart failure found that treatment with ACE inhibitorsincrease in cardiac afterload and preload and thereby
resulted in a significantly lower total mortality (15.8 vs.may further worsen left ventricular function. Treatments
21.9%) and lower combined hospitalization and mortal-that interfere or block these responses/systems may im-
ity (incidence 22.4 vs. 32.6%) [22]. This study demon-prove the performance of the left ventricle and may
strated that patients with the lowest ejection fractionrelieve symptoms. The long-acting nitrates are venodila-
benefited the most from this treatment.tors, which also have some effects on the arterial bed.
Despite these proven benefits, ACE inhibitors are onlyHydralazine, which has a potent arteriolar dilating effect,
prescribed in 40% of newly diagnosed heart failure pa-works synergistically with nitrates in patients with con-
tients in the community [23]. Furthermore, the dose usedgestive heart failure to decrease cardiac afterload and
thereby increases cardiac output. The combination of in practice is often less than that used in the clinical
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Fig. 1. Vicious cycle of depressed ventricular
function. Potential therapies are in parenthe-
ses. Abbreviations are: ACE-I, angiotensin con-
verting enzyme inhibitors; ARB, angiotensin
receptor blockers; AVP, arginine vasopressin.
trials. In heart failure patients, 10 mg b.i.d. of enalapril DIURETICS
and 50 mg t.i.d. of captopril are the target doses to treat Diuretics have been used for many years to treat the
ventricular dysfunction unless side effects developed. symptoms of congestive heart failure, and they continue
The combination of hydralazine and nitrates can be con- to represent a mainstay of heart failure therapy. The
sidered for patients who cannot tolerate ACE inhibitors successful use of neurohormonal interventions and vaso-
because of side effects (such as hyperkalemia, cough, or dilators in heart failure management depends on the
worsening renal function) [13–15]. appropriate use of diuretics. Specifically, over-diuresis
may lead to systemic hypotension and severe prerenal
azotemia when ACE inhibitors, other vasodilators, andDIGOXIN
b blockers are introduced in the heart failure patient.
A logical approach to treat congestive heart failure On the other hand, relative hypervolemia secondary to
caused by systolic dysfunction is to increase left ventricu- under-diuresis may lead to worsening heart failure dur-
lar contractility. The standard oral agent to achieve this ing initiation and up-titration of b blockers.
goal has been digoxin for the past 200 years. Digoxin When diuretics induce a natriuresis, the improved
inhibits the Na,K-ATPase pump, which causes an in- symptomatology relates primarily to the decrease in pul-
crease in intracellular calcium concentration [24]. The monary congestion, not an increase in the cardiac index.
consequence is an increase in myocyte contractility and Even prior to the onset of a diuresis, symptoms of pulmo-
ejection fraction in patients with heart failure caused by nary congestion can improve with loop diuretics such
systolic dysfunction. An acute administration of 1 mg of as furosemide, secondary to early venodilation with a
digoxin IV results in an increase in cardiac output and resultant decrease in cardiac preload [26]. Typical Frank-
a decrease in the pulmonary capillary wedge pressure Starling curves from a normal individual and a patient
[24]. In a recent double-blind, randomized study [25], with heart failure are shown in Figure 2. Therapy with
6800 patients with normal sinus rhythm, ejection fraction ACE inhibitors and b blockers causes a shift in the curve
of less than 45%, and NYHA class II or III who were with an increase of the stroke volume in patients with
receiving an ACE inhibitor were randomized to receive heart failure. Diuretics may improve pulmonary conges-
digoxin or placebo. Mortality was not affected, but there tion in a heart failure patient without decreasing cardiac
was a decrease in hospitalization caused by heart failure output if the cardiac index is on the flat part of the
curve relative to left ventricular end-diastolic pressurein the digoxin-treated group.
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stress, and ischemia [28], which is reversible with an
effective diuresis [29]. Thus, an improvement in cardiac
function may occur with sufficient fluid removal to sig-
nificantly decrease LVEDP, wall stress, and myocardial
ischemia. Increased extravascular pulmonary water has
also been suggested to cause an extracardiac impediment
to ventricular filling, an effect that could theoretically
be reversed by fluid removal from the lung [30]. An
increase in renal interstitial pressure has been shown to
activate the renin-angiotensin system, an effect that
could contribute to increased cardiac workload and myo-
cardial remodeling [31]. Fluid removal in edematous car-
diac failure patients could conceivably reverse such an
intrarenal effect. However, more often, diuretic use in
Fig. 2. Schematic representation of the Frank-Starling curve. Shift of cardiac failure patients is associated with increased acti-
the curve with the use of angiotensin converting enzyme (ACE) inhibi-
vation of the renin-angiotensin system, no doubt second-tors and b blockers. Abbreviations are: LV, left ventricular; LVEDP,
left ventricular end-diastolic pressure. ary to decreased cardiac index and worsening of arterial
underfilling.
Diuretic resistance (braking phenomenon) is not an
infrequent consequence of treatment of patients with
(LVEDP). However, in some circumstances, the di- advanced congestive heart failure. Since the intraluminal
uretic-induced natriuresis may actually decrease cardiac delivery by tubular secretion of loop diuretics is neces-
index, while improving the pulmonary congestion. In sary for these agents to inhibit sodium chloride reabsorp-
these patients, prerenal azotemia may occur with a dis- tion in the thick ascending limb of Henle’s loop, the
proportionate rise in blood urea nitrogen (BUN) as com- renal vasoconstriction associated with cardiac failure
pared with serum creatinine (.10:1 ratio). may contribute to relative diuretic resistance, necessitat-
Previously, it had been proposed that there was a ing higher doses of the drug. Avid tubular reabsorption
descending limb of the Frank-Starling curve whereby beyond the loop of Henle no doubt also contributes
a diuretic-induced loss of fluid and electrolytes would to diuretic resistance in heart failure patients. For this
actually be associated with an increase in cardiac index. reason, adding a more distal acting diuretic, such as meto-
Such a descending limb of the Frank-Starling curve, how- lazone or hydrochlorothiazide, may reverse the diuretic
ever, has not been documented in in vitro or in vivo resistance to loop diuretics [32, 33]. Since this combina-
model systems. Nevertheless, it does appear that in some tion may lead to profound renal potassium and magne-
patients, diuretic treatment of pulmonary congestion can sium wasting, there is a theoretical advantage to adding
actually improve cardiac function and prerenal azotemia a potassium-sparing diuretic, such as spironolactone or
[27]. The reasons for such clinical observations have not amiloride, rather than a thiazide diuretic, particularly
been well defined, but several possibilities exist. When since an increase in aldosterone activity frequently ac-
sufficient pulmonary congestion exists to be associated companies diuretic treatment of congestive heart failure
with hypoxia, carbon dioxide retention, and acidemia, [34]. Distal nephronal hypertrophy and increased Na,K-
these acid-base disorders may be associated with sup- ATPase activity have also been incriminated in diuretic
pression of myocardial contractility and increased sym- resistance [35]. The failures of dietary sodium restriction
pathetic and renin-angiotensin activity leading to in- and inadequate bed rest (which centralizes blood vol-
creased cardiac afterload. Treatment of the pulmonary ume) are also important features to evaluate as causes
congestion with diuretics or ultrafiltration, which reverse of diuretic resistance. Finally, loop diuretics have only
the hypoxia and acid-base disorders, will improve cardiac a four to six hour duration of action; therefore, once-
function. daily administration may be associated with an “appar-
Moreover, even in some patients with pulmonary con- ent” diuretic resistance, since sodium retention during
gestion in whom the potential hypoxia is prevented by the remaining 18 to 20 hours of the day may override
oxygen administration, a therapeutic removal of the fluid the shorter diuretic and natriuretic effects.
from the lungs may appear to improve cardiac and renal
function clinically. Although such improvement needs
b BLOCKERSbetter documentation, there are several possibilities to
explain such an effect. Cardiac dilation with fluid over- Perhaps the most exciting recent development in the
load and pulmonary congestion may be associated with treatment of chronic heart failure is the use of
b-adrenergic receptor blockers, such as carvedilol, thefunctional mitral insufficiency, increased myocardial wall
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only U.S. Food and Drug Administration-approved b losartan [43]. Since mortality was a secondary end point
blocker for the treatment of congestive heart failure. of the study and the number of patients was relatively
This third-generation nonselective b blocker has been small, confirmation of this potentially important finding
shown to attenuate disease progression defined by the was undertaken. This ELITE 2 study was unable to con-
combined end points of heart failure death, hospitaliza- firm an advantage of losartan over captopril.
tion for heart failure, and the need for a sustained in- Finally, ACE inhibitors decrease the production of
crease in heart failure medications [36–38]. In the U.S. angiotensin II, thereby decreasing the stimulation of
Carvedilol Heart Failure Trials Program, carvedilol pro- both AT1 and AT2 receptors, whereas the currently
duced a 65% reduction in mortality versus placebo when approved angiotensin receptor blockers are selective for
added to a regimen consisting of an ACE inhibitor and AT1 receptors. Thus, the administration of these angio-
a diuretic with or without digoxin [36]. Carvedilol not tensin receptor blockers is associated with an increase
only improved symptoms and survival and significantly in angiotensin II and AT2 receptor stimulation occurs.
increased left ventricular ejection fraction, it also had a It is postulated that AT2 stimulation may provide some
beneficial effect on myocardial remodeling. The Second myocardial protective effect, since blocking AT2 recep-
Cardiac Insufficiency Bisoprolol Survival trial (CIBIS II: tors in a preliminary study of animal models of heart
placebo controlled, randomized, double blind, 2647 pa-
failure abolished much of the benefit seen with the use
tients), which was terminated early, also supports the
of the AT1 receptor antagonists [44].use of b blockers in the management of chronic heart
On the other hand, in contrast to the initial ELITEfailure [39]. This study demonstrated a 34% reduction
study, preliminary results of another trial of angiotensinin all-cause mortality, a 44% reduction in sudden death,
II receptor blockade versus ACE inhibition in heart fail-a 36% reduction in hospitalizations for heart failure,
ure demonstrated a trend toward better outcomes inand a 20% reduction in all-cause hospitalization in the
patients treated with the ACE inhibitors, but this trendbisoprolol-treated patients.
did not reach statistical significance [45]. However, thisIn a recent review of 24 randomized b blockers versus
trial had too small of a sample size to conclusively defineplacebo, double-blinded trials for the treatment of heart
the role of angiotensin II receptor antagonists in thefailure involving 3141 patients, there was a relative re-
management of heart failure. Currently, angiotensin IIduction in mortality of 31% (7.5 vs. 9.7%) [40]. These
receptor blockers may be considered as an alternativebenefits were not significantly different between nonse-
for patients who do not tolerate ACE inhibitors and wholective b blockers with vasodilating property (carvedilol)
also fail to tolerate or to comply with the combinationand nonvasodilating b1 blockers (bisoprolol and meto-
of long-acting nitrates and hydralazine.prolol). These benefits were seen in both patients with
ischemic and nonischemic heart failure. The results of
other ongoing randomized studies of b blockers in heart
COMBINATION OF ANGIOTENSIN-CONVERTINGfailure should provide further information about the
ENZYME INHIBITORS AND ANGIOTENSINlong-term use of these agents in the treatment of chronic
RECEPTOR BLOCKERScardiac failure.
Some investigators have suggested that the combina-
tion of ACE inhibition and AT1 receptor blockade mayANGIOTENSIN II RECEPTOR ANTAGONISTS
be beneficial in heart failure. It has been demonstrated
While the angiotensin II type 1 (AT1) receptor antago-
that there is an alternative non-ACE pathway for localnists should produce effects similar to ACE inhibitors
production of angiotensin II within the myocardium [46].in cardiac failure patients, there are several differences.
This chymase-mediated increase in the tissue level ofThe most important is that ACE inhibitors have a more
angiotensin II in the heart could attenuate the benefitpronounced effect to increase bradykinin. Bradykinin’s
of long-term therapy with ACE inhibitors. In animalpotent vasodilator effect is due to endothelial nitric oxide
studies, the combination of both ACE inhibitors andrelease with subsequent cGMP activation in vascular
AT1 receptor antagonists in hypertensive rats, as wellsmooth muscle. It is also known that endogenous angio-
as rats with heart failure, showed an additive benefit thattensin II is not maximally suppressed long-term with
was superior to the use of either single agent at a higherACE inhibitor administration [41, 42], and thus, the AT1
dose [47]. These benefits have not been demonstratedreceptor blockers could theoretically be more effective
in humans. In the recent RESOLVD study, 601 patientsover time. In this regard, the recent Evaluation of Losar-
were randomized to candesartan, enalapril, or the combi-tan in the Elderly Study (ELITE) comparing the ACE
nation of both. There was no significant difference ininhibitor, captopril, to an AT1 receptor blocker, losartan,
the rate of mortality or hospitalization between the threein 722 older patients with heart failure demonstrated a
significantly better survival in those patients treated with groups at 43 weeks of follow-up [45].
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COMBINATION OF ANGIOTENSIN-CONVERTING OTHER AGENTS
ENZYME INHIBITORS AND SPIRONOLACTONE The orally active V2 receptor arginine vasopressin
(AVP) antagonists have been shown to attenuate waterThe combined use of aldosterone antagonists (for ex-
ample, spironolactone) and ACE inhibitors has been retention and correct dilutional hyponatremia in heart
failure patients [57]. However, it remains to be seenproposed as a strategy to optimize long-term benefit of
suppression of the renin-angiotensin-aldosterone sys- whether V1 receptor antagonists, V2 receptor antagonists,
or a combination of both will improve ventricular func-tem. In this regard, Pitt et al, on behalf of the Random-
ized Aldactone Evaluation Study (RALES) investigators tion and/or improve outcome in patients with cardiac
failure. These agents have yet to be approved by the[48], recently reported that in patients with heart failure
being treated with an ACE inhibitor and loop diuretic, Food and Drug Administration.
the addition of spironolactone at a dose of 25 to 50
mg/day for 24 months had decreased hospitalizations,
RENAL REPLACEMENT THERAPY FOR
symptomatology, and mortality. This effect of aldoste-
HEART FAILURE
rone antagonist may be secondary to a direct effect on
Fluid removal by intermittent or continuous ultrafil-the heart (e.g., decreased cardiac fibrosis).
tration has been suggested as an approach to reducing
excess extracellular fluid volume in advanced cardiac
OTHER INOTROPES failure, and some advantages over diuretic use have been
proposed [58–60]. Removal by ultrafiltration of cyto-The hope of positive inotropic agents as a treatment
for chronic cardiac failure has not been supported. In kines, which suppress myocardial contractility, has been
suggested as a potential, but as yet unproven, advantagefact, the continuous administration of nonglycoside ino-
tropic agents has consistently increased mortality in heart over diuretics in the treatment of heart failure. After
an acute activation of the neurohormonal responses tofailure patients [49–53]. That is, the administration of
ultrafiltration, and thus arterial underfilling, it has beenoral inotropic agents other than cardiac glycosides has
suggested that a diminution in these endogenous vaso-been associated with an increase in mortality, caused
constrictors (that is, angiotensin and norepinephrine)mainly by the proarrhythmic effects of these drugs. Al-
may occur and persist for up to several days to weeksthough the administration of intravenous inotropes such
[59]. This effect of ultrafiltration has been reported toas dobutamine in patients with refractory heart failure
be associated with diminished cardiac afterload and re-can improve acute heart failure and symptoms for up to
versal of diuretic resistance in some patients with conges-one month, a survival benefit has not been demonstrated.
tive heart failure. While initial removal of the circulating
norepinephrine may be greater with ultrafiltration as
OTHER VASODILATORS compared with diuretic treatment, the persistent benefit
Calcium channel blockers may have deleterious effects of ultrafiltration is difficult to explain. The initial in-
in heart failure patients because of their myocardial de- creased activation of the neurohormonal system, with
pressant effects [54, 55]. The dihydropyridine calcium either ultrafiltration or diuretics, occurs when the rate
channel blocker amlodopine may be the exception, hav- of fluid removal exceeds the rate of plasma refilling from
ing been shown not to increase mortality in heart failure the interstitial space, which is estimated to be 12 to 13
patients [56]. Further studies of these agents in heart mL/min in patients with heart failure [61].
failure patients are now underway. There are definite differences between ultrafiltration
Some clinicians combine ACE inhibition with nitrates and diuretic therapy to treat fluid overload and pulmo-
or hydralazine to decrease cardiac afterload and/or pre- nary congestion in patients with heart failure. Ultrafil-
load maximally and to increase the cardiac index. How- tration can be used when diuretic resistance is docu-
ever, as blood pressure and renal perfusion pressure mented after exclusion of reversible causes of diuretic
decline, sodium and water retention may worsen, so that resistance. Fluid and electrolyte as well as acid-base dis-
the deleterious effects of diminished renal function and orders are more easily corrected and avoided with ultra-
pulmonary congestion may negate the value of a modest filtration. Moreover, for the same amount of fluid re-
numerical increase in the cardiac index. Thus, a delicate moval, more sodium is removed with ultrafiltration than
balance between optimizing systemic hemodynamics and with diuretics, since the sodium concentration in the
maintaining renal perfusion within acceptable limits ultrafiltrate is the same as plasma, whereas with diuretics,
needs to be achieved in the heart failure patient. Some the urinary sodium concentration is virtually always less
modest increase in BUN and serum creatinine may be than plasma. Loop diuretics inhibit the Na/K/2 Cl-trans-
permissible to attain a well-compensated state. However, porter not only in the ascending limb of Henle’s loop,
great care should be employed when aggressive vasodila- but also in the macula densa. The latter effect is associ-
ated with a stimulation of the renin-angiotensin system,tor therapy is used in the management of heart failure.
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enalapril with hydralazine-isosorbide dinitrate in the treatment ofwhich may acutely increase cardiac afterload. There is no
congestive heart failure. N Engl J Med 325:300–310, 1991
evidence, however, that either ultrafiltration or diuretic 13. Konstam MA, Dracup K, Baker DW: Heart Failure: Evaluation
therapy prolongs life in the patient with advanced cardiac and Care of Patients with Left-Ventricular Systolic Dysfunction.
Clinical Practice Guideline Number 11. Rockville, Agency forfailure, even though the quality of life can clearly be
Health Care Policy and Research, 1994
improved. 14. Williams JF, Bristow MR, Fowler MB, Committee on Evalua-
tion and Management of Heart Failure: Guidelines for the
Evaluation and Management of Heart Failure. Report of the
American College of Cardiology/American Heart AssociationCONCLUSION
Task Force on Practice Guidelines. J Am Coll Cardiol 15:1376–
In recent years there have been important advances 1398, 1995
15. The Task Force of the Working Group on Heart Failure ofin the understanding and treatment of heart failure.
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